Skip to main content
. 2023 Apr 21;13:6528. doi: 10.1038/s41598-023-33848-y

Figure 7.

Figure 7

HIF-1α is involved in the activation of NLRP3 inflammasome in irinotecan (IR)-treated HepG2 cells. (A) Echinomycin (Ech) treatment suppresses NLRP3 inflammasome activity in IR-treated HepG2 cells. Western blot analysis of NLRP3, cleaved-Caspase1 and IL-1β protein levels in HepG2 cells. (B) Densitometric quantification of NLRP3, cleaved-Caspase1 and IL-1β. (C) Ech treatment alleviates ROS production in IR-treated HepG2 cells. Relative ROS level in each group. (D) Effects of ROS production on HIF-1α and NLRP3 inflammasome activity in IR-treated HepG2 cells. Western blot analysis of HIF-1α, NLRP3, cleaved-Caspase1 and IL-1β protein levels in HepG2 cells. (E) Densitometric quantification of HIF-1α, NLRP3, cleaved-Caspase1 and IL-1β. The blots were cut prior to hybridization with indicated primary antibodies. Data are presented as mean ± SD (n = 3), *P < 0.05 and **P < 0.01 compared with normal control group, #P < 0.05 and ##P < 0.01 compared with 20 μM IR-treated group.